You or someone you care for may have been recently diagnosed with cancer or you suffer from a recurrence or even metastatic disease?!
We wish to help you to learn about LentzLoc (an immune-based non-toxic cancer treatment) and its benefits in several cancers.
Due to its broad immunological profile the LentzLoc therapy can be applied to a wide range of cancer types and stages. LentzLoc is generally usable for most solid metastatic tumors, such as but not limited to:
Additionally, even rare conditions are generally treatable:
The following diseases cannot be treated with LentzLoc currently
The latest release of the LentzLoc technology is CE certified since February 2016 (i.e. it meets the essential requirements of all relevant European Medical Device Directives) so it can be used for cancer treatment in the entire European Union and other countries that acknowledge CE certification.
For many decades patients diagnosed with cancer had three major treatment options: Surgery, radiation therapy and chemotherapy.
However, patients have become more concerned about toxic side effects of established therapies as radiation and chemotherapy do not only kill cancer cells but may also create significant damage to healthy tissue. Especially patients in advanced/late stage cancer condition are searching for non-toxic treatment alternatives.
In more than 20 years of research of immunologic mechanics, scientists and physicians around the world have developed different immune based treatment approaches in order to fight cancer more precisely while lowering the side effects. Still, every cancer medication like chemo, antibodies, cancer-vaccines or other substances exposes your body to additional substances to deal with. Antibody therapies and cancer-vaccines still have the unpredictable disadvantage to create a potential overstimulation of the immune system and other side effects.
LentzLoc is a non-toxic alternative for immunological cancer treatment: As it is a subtractive onco-immune therapy, your body will not be exposed to potentially harmful medication, as only substances that protect cancer will be removed from your body through a medical device.
The cancer’s shield is removed in its direct microenvironment, so the treatment works directly on the primary tumor and all existing metastases.
The latest release of the LentzLoc technology comprises more than 15 years of immunological and therapeutic research and development in the United States and Germany. It is based on patents from the last 30 years. Throughout this time the technology has evolved through use in controlled clinical trials and treatment.
Non-scientifically explained: Your immune system would normally identify and destroy cancerous tissue through a number of mechanisms. A very important tool of your immune system uses against cancer is a substance called “Tumor necrosis factor” (TNF) which triggers cancer cell death. In rapidly growing cancers and especially metastatic cancer the primary tumor and all metastases produce a ‘cloaking shield’ around them granting effective protection against the immune system.
The substance forming this shield is called “soluble tumor necrosis factor receptors” (sTNF receptors). The shield blocks TNF and stops it from killing cancer cells. The more advanced the tumor is, the more substance is produced resulting in a stronger protection of the cancer.
Past efforts of stimulating or boosting the immune system in cancer patients has been largely ineffective.
The medical mechanism of LentzLoc is to cause an effective immunologic reaction against the cancer: Treatment with LentzLoc aims to remove the protection shield effectively, unleashing your immune system to fight the disease again. LentzLoc does not interfere with any healthy cells.
During the LentzLoc treatment a special filter, the plasma separator, separates the patient's blood into a cell-rich fraction and plasma.
The plasma passes the LentzLoc adsorption column that removes the cancer shield substance from the plasma. The patient’s own purified plasma – re-combined with the cell-rich blood - is led back to the patient subsequently.
The active principle of LentzLoc immunotherapy is based on four mechanisms:
The inflammatory reaction may cause a variety of immune effects, including transient tiredness, elevated temperatures and a short mild flu-like feeling. All these effects also occur with an intact immune system. Cancer patients with metastases may experience sensations at the tumor site(s).
Immunoadsorption effects a diverse immune modulation. The effects are still detectable after three to four weeks and may explain the clinical benefit.
The treatment results depend on the cancer progression and the cancer type. The therapy has shown very good results even in advanced stage/ late stage cancer cases.
Click here for the scientific explanation...
Patients and their caregivers are the ones who ultimately decide which treatment they want to pursue. The therapy aims to improve your overall quality of life during the oncological apheresis.
Optimal immune and clinical response against cancer is achieved by unblocking an otherwise healthy immune system and providing nutritional-, stress- management and good medical management of co- morbid medical conditions. This requires an experienced medical care team and medical setting.
Our clinicians are sensitive to your concerns and work to design treatment options that are appropriate for your needs and goals. Throughout your treatment, your care team will provide integrative oncology services, including nutrition therapy, naturopathic medicine and pain management.
Personalized physiotherapy, exercise and massages in a professional setting are available nearby.
Immunotherapy is a promising new treatment for solid cancer types, including advanced and recurrent forms of the disease; it may be used alone or in conjunction with other cancer treatments, such as surgery, in some cases anti-hormonal therapies and bisphosphonates (Zometa).
Your attending physician will monitor your progress closely and may pair LentzLoc with other supportive immunologic treatments. We are keen to provide you and your personal physician with the necessary information needed to make an informed decision about oncological apheresis.
We’re open from 9:00 a.m. to 5:00 p.m. Central European Time (Eastern Standard Time + 6 hours).
From within Germany: +49-8051-909-300
From EU to Germany: +49-8051-909-300
From the U.S.: 011-49-8051-909-300
From within Germany: +49-8051-909-301
From EU to Germany: +49-8051-909-301
From the U.S.: 011-49-8051-909-301